2024-10-21
Participating in CPHI Worldwid
Release Time: 2024-08-16
News Source: Reuters
Author: SENOVA—Lucas
COPENHAGEN, Aug 15 (Reuters) - Denmark's Zealand Pharma is set to start talks in the second half of this year with other pharmaceutical companies for potential partnerships to develop and commercialize its weight-loss drug petrelintide, its CEO told Reuters on Thursday.
"The reason that we need a big pharma partner along us at one point is to secure global reach but it's also because of investments into manufacturing," CEO Adam Steensberg told Reuters after the company reported second-quarter earnings.
In June, the Danish biotechnology company, which is developing a range of obesity drug candidates, said an early-stage study showed a high dose of its drug petrelintide helped reduce weight by an average 8.6% after 16 weekly doses.
"That is the most exciting data set ... for probably the history of Zealand," Steensberg said, adding that plans to start a mid-stage trial for the drug in the second half of this year was on track.
